Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Medication persistence and the use of generic and brand-name blood pressure-lowering agents.

Corrao G, Soranna D, La Vecchia C, Catapano A, Agabiti-Rosei E, Gensini G, Merlino L, Mancia G.

J Hypertens. 2014 May;32(5):1146-53; discussion 1153. doi: 10.1097/HJH.0000000000000130. Erratum in: J Hypertens. 2015 Jul;33(7):1495. J Hypertens. 2015 Oct;33(10):2181.

PMID:
24569417
2.

Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study.

Corrao G, Soranna D, Merlino L, Mancia G.

Eur J Clin Invest. 2014 Oct;44(10):933-9. doi: 10.1111/eci.12326.

PMID:
25132063
3.

Are generic and brand-name statins clinically equivalent? Evidence from a real data-base.

Corrao G, Soranna D, Arfè A, Casula M, Tragni E, Merlino L, Mancia G, Catapano AL.

Eur J Intern Med. 2014 Oct;25(8):745-50. doi: 10.1016/j.ejim.2014.08.002. Epub 2014 Sep 6.

PMID:
25200803
4.

[Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia].

Mainar AS, Artieda RN.

Gac Sanit. 2010 Nov-Dec;24(6):473-82. doi: 10.1016/j.gaceta.2010.07.007. Epub 2010 Oct 20. Spanish.

5.

Generic substitution of antihypertensive drugs: does it affect adherence?

Van Wijk BL, Klungel OH, Heerdink ER, de Boer A.

Ann Pharmacother. 2006 Jan;40(1):15-20. Epub 2005 Nov 22.

PMID:
16303985
6.

Comparative effectiveness of generic versus brand-name antiepileptic medications.

Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH.

Epilepsy Behav. 2015 Nov;52(Pt A):14-8. doi: 10.1016/j.yebeh.2015.08.014. Epub 2015 Sep 19.

8.

Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.

Ude M, Schuessel K, Quinzler R, Leuner K, Müller WE, Schulz M.

J Hypertens. 2011 Sep;29(9):1837-45. doi: 10.1097/HJH.0b013e32834942be.

PMID:
21738055
9.

Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.

Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH.

Ann Intern Med. 2014 Sep 16;161(6):400-7. doi: 10.7326/M13-2942.

PMID:
25222387
10.

Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims.

Mano Y, Fukushima S, Kuroda H, Ohshima H, Kato Y, Ohuchi K, Maezawa K, Momose Y, Ikeda S, Asahi M.

J Pharm Health Care Sci. 2015 Apr 1;1:12. doi: 10.1186/s40780-015-0013-8. eCollection 2015.

11.

Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.

Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, Brignoli O, Caputi AP.

J Hypertens. 2005 Nov;23(11):2093-100.

PMID:
16208153
12.

Effect of generic-only drug benefits on seniors' medication use and financial burden.

Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM.

Am J Manag Care. 2006 Sep;12(9):525-32.

13.

Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy.

Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G.

J Hypertens. 2008 Apr;26(4):819-24. doi: 10.1097/HJH.0b013e3282f4edd7.

PMID:
18327094
14.

Comparing recurrent antibiotic prescriptions in children treated with a brand name or a generic formulation.

Piovani D, Clavenna A, Cartabia M, Bortolotti A, Fortino I, Merlino L, Bonati M.

Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):121-8. doi: 10.1002/pds.3654. Epub 2014 Jun 9.

PMID:
24910387
15.

Generic drugs for hypertension: are they really equivalent?

Cooper-DeHoff RM, Elliott WJ.

Curr Hypertens Rep. 2013 Aug;15(4):340-5. doi: 10.1007/s11906-013-0353-4. Review.

16.

Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.

Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA.

Ann Intern Med. 2012 Jun 5;156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. doi: 10.7326/0003-4819-156-11-201206050-00004.

PMID:
22665815
17.
18.

Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy.

Colombo GL, Agabiti-Rosei E, Margonato A, Mencacci C, Montecucco CM, Trevisan R, Catapano AL.

Atheroscler Suppl. 2016 Jun;21:1-8. doi: 10.1016/j.atherosclerosissup.2016.02.001. Epub 2016 Feb 13.

19.

Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.

Navarro-Artieda R, Rejas-Gutiérrez J, Pérez-Paramo M, Sicras-Mainar A.

Neurologia. 2016 Jun 16. pii: S0213-4853(16)30043-3. doi: 10.1016/j.nrl.2016.03.012. [Epub ahead of print] English, Spanish.

20.

Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.

Liu YM, Ou HT, Yang YK.

J Ment Health Policy Econ. 2014 Dec;17(4):163-72.

PMID:
25599280

Supplemental Content

Support Center